Q-omics provides the consensus-scored CCDC140 profile across patient tissues and cancer cell-line models. CCDC140 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CCDC140 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, CCDC140 RNA expression shows 9,986 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where CCDC140 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC140 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC140 survival associations across molecular data types. CCDC140 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC140 RNA expression–survival associations across cancer types. High CCDC140 expression shows unfavorable associations in COAD, KIRC, LGG, READ, UVM and STAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CCDC140 RNA expression.
This table summarizes CCDC140 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC140. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC140 shows lower tumor expression in BRCA and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher CCDC140 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p = .015).
This table shows molecular features associated with CCDC140 in patient tissues and cancer cell lines. In patient samples, CCDC140 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC140 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
